Investigation of interindividual factors in erlotinib and its metabolites pharmacokinetics, clinical responses and adverse reactions in Japanese non-small cell lung cancer patients receiving oral erlotinib.
Phase of Trial: Phase IV
Latest Information Update: 20 Mar 2014
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacokinetics
- 20 Mar 2014 New trial record